GRCE
Grace Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$50.53M
P/E Ratio
—
EPS
$-0.31
Beta
0.69
52W High
$5.18
52W Low
$1.88
50-Day MA
$4.05
200-Day MA
$3.41
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.17
PEG Ratio
—
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in Princeton, New Jersey.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.24M |
| Operating Margin | 0.00% |
| Return on Equity | -10.20% |
| Return on Assets | -10.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.19 |
| Price-to-Book | 1.22 |
| Price-to-Sales (TTM) | 197.75 |
| EV/Revenue | 5.5 |
| EV/EBITDA | 19.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $14.13M |
| Float | $9.77M |
| % Insiders | 27.06% |
| % Institutions | 28.00% |
Data last updated: 4/8/2026